Skip to main content

Advertisement

Table 2 Summary of efficacy

From: Intra-articular injection of the anti-inflammatory compound LMWF-5A in adults with severe osteoarthritis: a double-blind prospective randomized controlled multi-center safety and efficacy trial

Responder rate, % (95% CI) OMERACT-OARSIResponder Controlled Responder PGA responder
Week 2 66.0 (58.2–73.7) 54.2 (46.0–62.3) 66.0 (58.2–73.7)
Week 6 66.0 (58.2–73.7) 58.3 (50.3–66.4) 61.8 (53.9–69.7)
Week 10 72.2 (64.9–79.5) 61.8 (53.9–69.7) 72.9 (65.7–80.2)
Week 12 70.8 (63.4–78.3) 64.6 (56.8–72.4) 66.0 (58.2–73.7)
  1. CI confidence interval, OMERACT-OARSI Outcome Measures in Rheumatology (OMERACT) - Osteoarthritis Research Society International (OARSI), PGA Patient Global
  2. Assessment. Efficacy endpoints were analyzed with one-sided exact binomial test compared to null hypothesis of 30% responder rate. P < 0.001 for all responder rates at all time points